Phase III Trial of mRNA Vaccine Against H5N1 Bird Flu Starts in UK and US
A phase III trial for the mRNA-1018 vaccine targeting H5N1 bird flu has begun in the UK and US, involving 4000 volunteers. The trial focuses on immune response strength amid ongoing global spread of the virus in animals. Funded by CEPI, it follows successful earlier phases with no safety issues.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)A phase III trial of an mRNA vaccine against the H5N1 bird flu strain has started in the UK and the US, @NewScientist reported. The mRNA-1018 vaccine, which has already completed phase I and II trials with no safety concerns identified, will involve 3000 volunteers in the UK and 1000 in the US.
The trial prioritizes people aged over 65 and those who work with poultry, as these groups face higher risks from the virus.
Since H5N1 bird flu is not spreading among people, the phase III trial will measure the strength of the immune response in volunteers rather than direct effectiveness. “A flu pandemic is the most likely future pandemic. And it’s really critical that we ensure we’re properly prepared,” said Richard Pebody at the UK Health Security Agency, as quoted by @NewScientist.
Results from earlier trials indicate the vaccine evokes a strong immune response, according to Hiwot Hiruy at Moderna. The trial is funded by the Coalition for Epidemic Preparedness Innovations (CEPI), which is backed by more than 30 countries and other organizations. This funding came after the US government cut support for mRNA vaccines.
“We cannot predict the timing or the severity of the next pandemic. However, with continued circulation of influenza viruses in animal populations, and the potential for virus adaptation, preparedness remains essential,” Hiruy stated. The UK has stockpiled 5 million doses of conventional vaccines against H5N1 bird flu, produced using chicken eggs.
These existing vaccines differ from the mRNA approach, which allows for rapid scaling and easy modifications if the virus evolves. Pebody noted that mRNA vaccines offer major advantages for pandemic preparation due to their flexibility in production.
A study in France found that vaccinating ducks dramatically reduced H5N1 outbreaks on farms, highlighting potential benefits for animal vaccination strategies.
Countries like the UK and US may consider rolling out H5N1 vaccines for farm animals, particularly poultry, building on such approaches used elsewhere. 4b has spread globally in wild birds since evolving around a decade ago. This strain has reached the Antarctic and has been circulating in dairy cattle in the US.
Many wild mammals have been infected by wild birds, and it has often spread to poultry farms. There have been more than 100 human cases of H5N1 bird flu since 2024. Despite these infections, there is no evidence of the virus spreading from person to person.
As long as H5N1 continues circulating, the risk of adaptation persists, underscoring the need for ongoing preparedness efforts.
Key Facts
Story Timeline
6 events- 2026-04-30
Phase III trial of mRNA-1018 vaccine against H5N1 bird flu starts in the UK and US.
1 source@NewScientist - Prior to 2026
Phase I and II trials of mRNA-1018 vaccine completed with no safety concerns.
1 source@NewScientist - Since 2024
More than 100 human cases of H5N1 bird flu reported, with no person-to-person spread.
1 source@NewScientist - Around 2016
H5N1 clade 2.3.4.4b strain evolved and began spreading globally in wild birds.
1 source@NewScientist - Recent years
H5N1 clade 2.3.4.4b reached the Antarctic and circulated in US dairy cattle.
1 source@NewScientist - Recent
US government cut funding for mRNA vaccines; CEPI stepped in to fund the trial.
1 source@NewScientist
Potential Impact
- 01
Increased preparedness for high-risk groups like the elderly and poultry workers through targeted vaccination.
- 02
Shift from egg-based to mRNA vaccines may improve scalability and adaptability for evolving viruses.
- 03
Potential approval of mRNA vaccine could enable faster response to a bird flu pandemic.
- 04
Possible rollout of animal vaccines in countries like UK and US, reducing farm outbreaks.
- 05
Ongoing monitoring of H5N1 could prevent human-to-human transmission risks.
Transparency Panel
Related Stories
NASA Releases Thousands of Photos from Artemis II Lunar Mission
NASA has released over 12,000 images from the Artemis II mission, which orbited the moon in April 2026. The photos capture views of Earth, the lunar surface, and a solar eclipse observed during the crew's return. Astronauts from the mission also visited the United Nations headqua…
newscientist.comHoutman Abrolhos Corals Show High Resilience to 2025 Heatwave, Unlike Global Losses
Coral reefs at the Houtman Abrolhos Islands off Western Australia endured a prolonged heatwave in early 2025 virtually unscathed, unlike widespread global die-offs. Researchers found exceptional heat tolerance across multiple species, with lab tests showing survival rates far exc…
deccanchronicle.comHantavirus Cases Reported on MV Hondius Cruise Ship, Three Fatalities Amid Low Transmission Risk
A hantavirus outbreak on the MV Hondius cruise ship has killed three passengers and sickened seven others, prompting an international response coordinated by the World Health Organization. The ship, carrying 147 people from 23 nationalities, is set to sail to Spain's Canary Islan…